Status:

COMPLETED

Efficacy of Neural Prolotherapy for Treatment of Anserine Bursitis "NPCAB"

Lead Sponsor:

University of Alexandria

Conditions:

Anserine Bursitis

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Anserine bursitis is a common etiology of medial knee pain. It could be severe enough to limit the patient's functional abilities with affection of the quality of life. The etiology of AB is unknown. ...

Detailed Description

Anserine bursitis is a common etiology of medial knee pain. It could be severe enough to limit the patient's functional abilities with affection of the quality of life. The etiology of AB is unknown. ...

Eligibility Criteria

Inclusion

  • Chronic anserine bursitis was based on clinical manifestations, which was the presence of pain in the medial and inferior aspect of the knee. It was increased during going upstairs and downstairs associated with tenderness on the inferomedial aspect of the knee joint about 5 cm below the medial knee joint line and occasionally local swelling. It could be associated with morning pain and stiffness.
  • Patients who were refractory to conservative treatment for at least 3 months were considered to have chronic anserine bursitis. Each knee was assessed separately for eligibility.

Exclusion

  • Symptomatic knee osteoarthritis.
  • Internal derangement of the knee.
  • Previous knee surgery.
  • Prior surgery in the affected knee region.
  • Systemic rheumatologic disorders.
  • Fibromyalgia.
  • Diabetes mellitus.
  • Endocrine disorders.
  • Metabolic disorders.
  • Coagulopathy.
  • Anticoagulant treatment.
  • Current skin or soft tissue infection at or near the site of injection.
  • Prior local soft tissue injection of corticosteroid for anserine bursitis in the past year.
  • Prior neural prolotherapy for anserine bursitis in the past year.
  • Patients presented with a systemic active inflammatory condition or infection.
  • Pregnancy.
  • Unwillingness to participate in the study.
  • History of allergy to the used corticosteroid and/or local anaesthetic.

Key Trial Info

Start Date :

May 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 30 2019

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT04509440

Start Date

May 1 2018

End Date

October 30 2019

Last Update

August 12 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Faculty of Medicine, Alexandria University

Alexandria, Egypt, 21131